glp 1 agonist medullary thyroid cancer Does Using GLP-1 Drugs, Like Zepbound or Wegovy, Increase Your Risk of Cancer? Thyroid cancer survivor wondering about

Lets look at each one

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

A 2022 study published in Diabetes, Obesity and Metabolism found that adults over 50 achieved clinically significant weight loss on semaglutide, with cardiovascular and metabolic risk reductions comparable to younger cohorts, though the authors noted the importance of individualized monitoring protocols for older patients given the higher baseline prevalence of comorbidities

#Obesity #Biotech #PharmaPipeline #ClinicalTrials #LifeSciences To view or add a comment, sign in The GLP-1 Revolution: What Every Cardiologist/Physician Should Know We used to think of semaglutide and liraglutide as "diabetes drugs." That framing is now obsolete

30 , 31 The FLOW trial demonstrated that, compared to placebo, randomization to semaglutide reduced the risk of kidney-related complications by 24% (HR: 0.76, 95% CI 0.66, 0.88) in patients with diabetes and chronic kidney disease